American Association for Cancer Research
Browse
15417786mcr060034-sup-supplementary_table_s4.xls (56 kB)

Supplementary Table S4 from Identification and Validation of Colorectal Neoplasia–Specific Methylation Markers for Accurate Classification of Disease

Download (56 kB)
dataset
posted on 2023-04-03, 18:22 authored by Fabian Model, Neal Osborn, David Ahlquist, Robert Gruetzmann, Bela Molnar, Ferenc Sipos, Orsolya Galamb, Christian Pilarsky, Hans-Detlev Saeger, Zsolt Tulassay, Kari Hale, Suzanne Mooney, Joseph Lograsso, Peter Adorjan, Ralf Lesche, Andreas Dessauer, Joerg Kleiber, Baerbel Porstmann, Andrew Sledziewski, Catherine Lofton-Day
Supplementary Table S4 from Identification and Validation of Colorectal Neoplasia–Specific Methylation Markers for Accurate Classification of Disease

History

ARTICLE ABSTRACT

Aberrant DNA methylation occurs early in oncogenesis, is stable, and can be assayed in tissues and body fluids. Therefore, genes with aberrant methylation can provide clues for understanding tumor pathways and are attractive candidates for detection of early neoplastic events. Identification of sequences that optimally discriminate cancer from other diseased and healthy tissues is needed to advance both approaches. Using well-characterized specimens, genome-wide methylation techniques were used to identify candidate markers specific for colorectal neoplasia. To further validate 30 of these candidates from genome-wide analysis and 13 literature-derived genes, including genes involved in cancer and others with unknown functions, a high-throughput methylation-specific oligonucleotide microarray was used. The arrays were probed with bisulfite-converted DNA from 89 colorectal adenocarcinomas, 55 colorectal polyps, 31 inflammatory bowel disease, 115 extracolonic cancers, and 67 healthy tissues. The 20 most discriminating markers were highly methylated in colorectal neoplasia (area under the receiver operating characteristic curve > 0.8; P < 0.0001). Normal epithelium and extracolonic cancers revealed significantly lower methylation. Real-time PCR assays developed for 11 markers were tested on an independent set of 149 samples from colorectal adenocarcinomas, other diseases, and healthy tissues. Microarray results could be reproduced for 10 of 11 marker assays, including eight of the most discriminating markers (area under the receiver operating characteristic curve > 0.72; P < 0.009). The markers with high specificity for colorectal cancer have potential as blood-based screening markers whereas markers that are specific for multiple cancers could potentially be used as prognostic indicators, as biomarkers for therapeutic response monitoring or other diagnostic applications, compelling further investigation into their use in clinical testing and overall roles in tumorigenesis. (Mol Cancer Res 2007;5(2):153–63)

Usage metrics

    Molecular Cancer Research

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC